Bicalutamide treatment for locally advanced prostate cancer

被引:3
作者
Anderson, J [1 ]
机构
[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
来源
HOSPITAL MEDICINE | 2000年 / 61卷 / 09期
关键词
D O I
10.12968/hosp.2000.61.9.1426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In men with locally advanced prostate cancer, bicalutamide 150mg monotherapy provides a similar disease outcome to medical or surgical castration. However, castration is associated with loss of sexual interest and function, decreased energy and an increased risk of osteoporotic fractures. Bicalutamide 150mg monotherapy has less impact on sexual interest and physical capacity than castration.
引用
收藏
页码:660 / 663
页数:4
相关论文
共 17 条
[1]  
[Anonymous], 1997, AM J MED
[2]  
BUCHHOLZ NP, 1994, Z GERONTOL, V27, P334
[3]   Progressive osteoporosis during androgen deprivation therapy for prostate cancer [J].
Daniell, HW ;
Dunn, SR ;
Ferguson, DW ;
Lomas, G ;
Niazi, Z ;
Stratte, PT .
JOURNAL OF UROLOGY, 2000, 163 (01) :181-186
[4]   Quality of life issues relating to endocrine treatment options [J].
Iversen, P .
EUROPEAN UROLOGY, 1999, 36 :20-26
[5]  
IVERSEN P, 2000, IN PRESS J UROL
[6]   Treatment options for early prostate cancer [J].
Kirby, R .
UROLOGY, 1998, 52 (06) :948-962
[7]   Prostate cancer and sexual function [J].
Kirby, RS ;
Watson, A ;
Newling, DWW .
PROSTATE CANCER AND PROSTATIC DISEASES, 1998, 1 (04) :179-184
[8]  
Kolvenbag GJCM, 1999, PROSTATE, V39, P47, DOI 10.1002/(SICI)1097-0045(19990401)39:1<47::AID-PROS8>3.0.CO
[9]  
2-X
[10]   PATIENT PREFERENCES - SURVIVAL VS QUALITY-OF-LIFE CONSIDERATIONS [J].
MAZUR, DJ ;
HICKAM, DH .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1993, 8 (07) :374-377